The Joe Rogan ExperienceJoe Rogan Experience #1661 - Rick Doblin
CHAPTERS
- 0:00 – 1:56
Why MAPS Focused on PTSD: From Soldiers to Police (and the case for prisons)
Joe praises Rick Doblin and MAPS for choosing PTSD—especially in veterans—as the most publicly compelling place to prove psychedelic therapy’s value. Doblin describes surprising study participants like police officers and explores why prisoners and prison guards could benefit too, while acknowledging ethical hurdles.
- 1:56 – 5:21
Timothy Leary’s Concord Prison Experiment: What went wrong and what it taught
Doblin explains his follow-up on Leary’s prison psilocybin study and reveals data manipulation and misleading claims. The broader lesson, he argues, is that psychedelics alone aren’t enough—aftercare and community support are essential for lasting change, especially post-release.
- 5:21 – 8:43
Integration and the ‘Ctrl-Alt-Delete’ metaphor: Why people revert to old habits
Joe argues psychedelic breakthroughs often fade because people return to familiar patterns without a new structure. Doblin connects this to 1960s ‘one-dose miracle’ thinking and emphasizes integration, neuroplasticity, and therapy as the real drivers of durable change.
- 8:43 – 16:14
A rare one-session PTSD resolution: Tony Macy’s MDMA breakthrough
Doblin shares an exceptional case where a veteran’s PTSD resolved after a single MDMA session through a reframing of loyalty and survivor guilt. Joe expands on the deep bonds among soldiers and how healing can transform guilt into advocacy for fellow veterans.
- 16:14 – 19:25
Doblin’s early life and ‘the underground’: Russia, the Cold War, and meeting the “other”
Doblin recounts his teenage trip to the USSR, black-market exchanges, and covertly delivering forbidden Jewish prayer books. The experience reshaped his perception of enemies and foreshadows his later belief that connection-oriented experiences can reduce conflict.
- 19:25 – 25:26
DMT with Terence McKenna and ketamine’s ‘Hitler’ vision: mass psychology and political strategy
Doblin describes a DMT insight about interconnectedness that forced him to confront humanity’s capacity for evil. A ketamine experience around Hitler’s rallies leads to a strategic lesson: changing society requires shifting the ‘many,’ not just leaders—building mass mental health and compassion.
- 25:26 – 31:12
War, stimulants, and propaganda: drugs in the Third Reich and beyond
Joe and Rick discuss historical drug use—Hitler’s doctoring, amphetamines in Nazi troops, and stimulants in wartime more broadly. The conversation pivots to how society’s anti-drug moralism ignores that brains themselves are ‘drug factories’ and that legal drugs shape behavior too.
- 31:12 – 45:17
Carl Hart, MAPS culture, and ‘smokable tasks’: drug policy reform meets workplace reality
They celebrate Carl Hart’s data-driven contrarianism and his potential role with MAPS. Doblin explains MAPS’ performance-based approach (no drug testing) and formal acceptance of limited cannabis use for certain tasks, sparking a wider discussion on creativity and altered association networks.
- 45:17 – 51:58
Building psychedelic care infrastructure: thousands of clinics, cross-trained therapists, and education reform
Doblin predicts a future with thousands of psychedelic therapy centers, akin to today’s ketamine clinics, and outlines anticipated FDA timelines. The conversation broadens into how schools overemphasize cognitive learning while neglecting emotional education—fueling dysfunction and overmedication.
- 51:58 – 1:08:38
How Doblin committed to psychedelics: Grof’s manuscript, primal therapy, and learning integration the hard way
Doblin recounts dropping out of college to study psychedelics, getting unexpected institutional support, and reading an early Grof manuscript that reframed his experiences as science and therapy. After years of confusion and overuse, he learns the centrality of integration—then later discovers MDMA before its backlash and turns political.
- 1:08:38 – 1:21:36
Psychedelics, spirituality, and research integrity: the Good Friday Experiment follow-up
Doblin explains Walter Pahnke’s landmark Good Friday psilocybin study and why its Mystical Experience Questionnaire remains influential. He describes his later follow-up research—confirming lasting benefits while uncovering hidden adverse events and exaggerated claims, reinforcing the need for honest reporting and proper safeguards.
- 1:21:36 – 1:48:01
From MKUltra to ‘non-psychedelic psychedelics’: military interest, policy, and bipartisan momentum
They trace dark historical uses of psychedelics (mind control, incapacitation) and contrast them with today’s therapeutic aims for veterans. Doblin critiques efforts to remove the subjective ‘trip’ while keeping neuroplasticity, then details bipartisan congressional moves and growing military endorsements for psychedelic research.
- 1:48:01 – 2:12:26
Cannabis policy battles and veteran research: ending the federal supply monopoly
Doblin details MAPS’ long legal fight to end the U.S. government’s monopoly on research cannabis and the problems it caused for clinical trials. He discusses new state-funded veteran studies (Colorado, Michigan), the surprising placebo effects, and predicts federal deprohibition by 2025 while debating Texas’ slow adoption.
- 2:12:26 – 2:59:56
How MAPS will commercialize MDMA therapy: trials, dosing, training, FDA disputes, and scaling access
Doblin lays out the phase 3 PTSD results, dosing logic, and the practical obstacles to scaling (therapist availability, insurance, and regulatory requirements). He explains MAPS’ nonprofit + Public Benefit Corporation structure, data exclusivity strategy, manufacturing realities, and a successful challenge to FDA constraints on therapist training protocols.
- 2:59:56 – 3:15:32
Beyond PTSD: prisons, reconciliation work, octopus empathy, and a call to support MAPS
They return to prisons as a long-term target—likely beginning with parolees—then broaden to political reconciliation projects (Israel–Palestine) and the biology of empathy, including MDMA’s effects across species. The episode closes with MAPS fundraising needs and how listeners can donate and support the rollout of psychedelic medicine.
